Literature DB >> 27312404

Lost in Translation: CRF1 Receptor Antagonists and Addiction Treatment.

Yavin Shaham1, Harriet de Wit2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27312404      PMCID： PMC5061894          DOI： 10.1038/npp.2016.94

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  18 in total

Review 1.  CRF and CRF receptors: role in stress responsivity and other behaviors.

Authors:  Tracy L Bale; Wylie W Vale
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

2.  Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor.

Authors:  Beth A Fleck; Sam R J Hoare; Rebecca R Pick; Margaret J Bradbury; Dimitri E Grigoriadis
Journal:  J Pharmacol Exp Ther       Date:  2012-02-22       Impact factor: 4.030

Review 3.  Translational and reverse translational research on the role of stress in drug craving and relapse.

Authors:  Rajita Sinha; Yavin Shaham; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2011-04-15       Impact factor: 4.530

Review 4.  Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.

Authors:  Florian Holsboer; Marcus Ising
Journal:  Eur J Pharmacol       Date:  2008-01-24       Impact factor: 4.432

5.  Corticotropin-releasing factor and behavior.

Authors:  G F Koob; F E Bloom
Journal:  Fed Proc       Date:  1985-01

6.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

Authors:  W Vale; J Spiess; C Rivier; J Rivier
Journal:  Science       Date:  1981-09-18       Impact factor: 47.728

7.  The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle.

Authors:  Christian Grillon; Elizabeth Hale; Lynne Lieberman; Andrew Davis; Daniel S Pine; Monique Ernst
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

8.  Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats.

Authors:  Y Shaham; D Funk; S Erb; T J Brown; C D Walker; J Stewart
Journal:  J Neurosci       Date:  1997-04-01       Impact factor: 6.167

9.  Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study.

Authors:  L W Swanson; P E Sawchenko; J Rivier; W W Vale
Journal:  Neuroendocrinology       Date:  1983       Impact factor: 4.914

Review 10.  The role of CRF and CRF-related peptides in the dark side of addiction.

Authors:  George F Koob
Journal:  Brain Res       Date:  2009-11-11       Impact factor: 3.252
View more
  19 in total

Review 1.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

2.  Prevention and reversal of social stress-escalated cocaine self-administration in mice by intra-VTA CRFR1 antagonism.

Authors:  Xiao Han; Joseph F DeBold; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2017-07-11       Impact factor: 4.530

Review 3.  Probing for Neuroadaptations to Unpredictable Stressors in Addiction: Translational Methods and Emerging Evidence.

Authors:  Jesse T Kaye; Daniel E Bradford; Katherine P Magruder; John J Curtin
Journal:  J Stud Alcohol Drugs       Date:  2017-05       Impact factor: 2.582

4.  Addiction research and theory: a commentary on the Surgeon General's Report on alcohol, drugs, and health.

Authors:  Aldo Badiani; Kent C Berridge; Markus Heilig; David J Nutt; Terry E Robinson
Journal:  Addict Biol       Date:  2017-02-21       Impact factor: 4.280

5.  Enhanced CRFR1-Dependent Regulation of a Ventral Tegmental Area to Prelimbic Cortex Projection Establishes Susceptibility to Stress-Induced Cocaine Seeking.

Authors:  Oliver Vranjkovic; Erik C Van Newenhizen; Michael E Nordness; Jordan M Blacktop; Luke A Urbanik; Jacob C Mathy; Jayme R McReynolds; Anna M Miller; Elizabeth M Doncheck; Tyler M Kloehn; Gwen S Stinnett; Clayton H Gerndt; Kyle D Ketchesin; David A Baker; Audrey F Seasholtz; John R Mantsch
Journal:  J Neurosci       Date:  2018-10-24       Impact factor: 6.167

Review 6.  A Rationale for Allopregnanolone Treatment of Alcohol Use Disorders: Basic and Clinical Studies.

Authors:  A Leslie Morrow; Giorgia Boero; Patrizia Porcu
Journal:  Alcohol Clin Exp Res       Date:  2019-12-17       Impact factor: 3.455

7.  Stress Allostasis in Substance Use Disorders: Promise, Progress, and Emerging Priorities in Clinical Research.

Authors:  Gaylen E Fronk; Sarah J Sant'Ana; Jesse T Kaye; John J Curtin
Journal:  Annu Rev Clin Psychol       Date:  2020-02-10       Impact factor: 18.561

8.  Persistent escalation of alcohol consumption by mice exposed to brief episodes of social defeat stress: suppression by CRF-R1 antagonism.

Authors:  Emily L Newman; Lucas Albrechet-Souza; Peter M Andrew; John G Auld; Kelly C Burk; Lara S Hwa; Eric Y Zhang; Joseph F DeBold; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2018-04-25       Impact factor: 4.530

Review 9.  Medications for alcohol use disorders: An overview.

Authors:  Mohammed Akbar; Mark Egli; Young-Eun Cho; Byoung-Joon Song; Antonio Noronha
Journal:  Pharmacol Ther       Date:  2017-12-02       Impact factor: 12.310

Review 10.  Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications.

Authors:  Daniele Caprioli; Zuzana Justinova; Marco Venniro; Yavin Shaham
Journal:  Biol Psychiatry       Date:  2017-09-05       Impact factor: 13.382
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.